I am concerned with the way the market has been treating AHZ which is at a more advanced stage atm. whilst I concede the potential market for stents is much bigger, RVA still has to deal with manufacturing and then marketing and what can often be a slow adoption of the technology by the medical fraternity. as the market is being very unimaginative and seems to be demanding sales figures before responding with AHZ I fear a similar treatment of RVA awaits us and there will be a period of prolonged shorting. especially when the options mature. it is already well above BP's reco on no new factors
hope I am wrong. DYOR
herbaliser
RVA Price at posting:
46.0¢ Sentiment: Hold Disclosure: Held
